Four researchers from the USA Health Mitchell Cancer Institute and the Frederick P. Whiddon College of Medicine at the University of South Alabama recently were awarded grants from the Breast Cancer Research Foundation of Alabama (BCRFA). Presented during an event in Birmingham last December, the a...
Susan Galbraith, MBBChir, PhD, executive vice president of oncology research & development at AstraZeneca highlighted that this breakthrough designation brings a potential new option in earlier lines of treatment for HER2 positive metastatic breast cancer. “This recognition by the F...
FDA Oncology Center of Excellence director, said in a statement. "Chemotherapy has been the mainstay of treatment for triple-negative breast cancer. The approval of Trodelvy today represents a new targeted therapy for patients living with this aggressive ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
FDA Grants Accelerated Approval to Tucatinib Combination for Patients with HER2-Positive Metastatic Colorectal Cancer Erin Hunter, Assistant Editor January 20th 2023 This is the first indication for tucatinib that extends beyond the treatment of advanced unresectable or metastatic HER2-positive breast cancer...
Patients With Breast Cancer and Depression May Have a Lower Likelihood of Survival Alana Hippensteele, Managing Editor June 16th 2023 Depression can affect the trajectory of treatment and associated outcomes. Read More FDA Grants Priority Review to Capivasertib Combination for Locally Advanced, Metastati...
2. Current landscape of therapeutic vaccines for breast cancer 3. Vaccines targeting HER2 in breast cancer 4. Vaccines targeting triple-negative breast cancer 5. Vaccines targeting HR-positive breast cancer 6. Vaccines targeting breast cancer irrespective of the biological subtype 7. Other targets for...
AstraZeneca oncology R&D executive vice-president José Baselga said: “Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today. ...
You’re never too young to start planning a life without breast cancer! We support woman by offering grants for supplemental screening and diagnostic testing
One of the major recent clinical advances in cancer treatment is the use of antiangiogenic drugs such as bevacizumab, sorafenib, and sunitinib. Bevacizumab, the monoclonal anti-VEGF antibody, has been approved for the first line treatment of metastatic breast cancer (MBC) when combined with taxane...